Orris

Give me highly conceptual high yield clinical application based mcqs on anti arrythmia drugs , pharmacology from katzung good man and gill man KDT

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have excellent, rich source material from Katzung and Goodman & Gilman. I have everything I need to craft high-yield, conceptually deep, clinically applied MCQs. Let me now compile the comprehensive MCQ set.

High-Yield Clinical Application MCQs: Antiarrhythmic Drugs

From Katzung's Basic & Clinical Pharmacology | Goodman & Gilman's Pharmacological Basis of Therapeutics | Goldman-Cecil Medicine

BLOCK 1: Vaughan Williams Classification & Mechanism

Q1. A 58-year-old man is brought to the ER with sustained monomorphic ventricular tachycardia at 180 bpm. He has a history of prior MI with an EF of 30%. IV lidocaine is administered and successfully terminates the arrhythmia. Which of the following best explains lidocaine's selectivity for ischemic myocardium over normal tissue?
A. Lidocaine binds exclusively to inactivated sodium channels in ischemic zones where resting potential is chronically depolarized to less than -75 mV B. Lidocaine increases automaticity in the His-Purkinje system to outpace the ectopic focus C. Lidocaine blocks IKr channels preferentially in hypoxic tissue D. Lidocaine activates the Na+/K+-ATPase pump, restoring normal resting potential E. Lidocaine undergoes preferential uptake by ischemic myocytes due to altered membrane permeability
Correct Answer: A
Explanation: Lidocaine is a class IB antiarrhythmic that demonstrates use-dependent and state-dependent sodium channel blockade. In ischemic myocardium, cells are chronically depolarized (resting potential more positive than -75 mV), keeping sodium channels in the inactivated state. Lidocaine binds with high affinity to inactivated channels and dissociates from rested channels very rapidly. In normal cells, channels quickly recover to the rested state during diastole and lose the drug. In chronically depolarized ischemic cells, recovery from block is extremely slow, causing selective accumulation of block. This "state-dependent" mechanism is the textbook basis for lidocaine's anti-ischemic selectivity. (Katzung, Figure 14-9; block3.md)
Q2. A pharmacology student is studying sodium channel blockers and notes that Class 1A drugs "prolong APD with intermediate dissociation kinetics," 1B drugs "shorten or do not change APD with fast dissociation," and 1C drugs "markedly slow conduction with slow dissociation." Which of the following clinical observations best reflects the slow dissociation kinetics of a Class 1C drug?
A. Flecainide causes greater depression of conduction at faster heart rates and is dangerous in post-MI patients even at rest B. Quinidine causes torsades de pointes due to IKr blockade at bradycardic rates C. Lidocaine is ineffective in atrial fibrillation D. Mexiletine can be combined with quinidine for additive sodium channel blockade E. Procainamide widens the QRS complex only during tachycardia
Correct Answer: A
Explanation: Because 1C drugs (flecainide, propafenone) have slow dissociation kinetics, drug accumulates in sodium channels at normal heart rates - it does not fully wash out during diastole. At faster rates (more activations per minute), even less drug leaves between beats, causing progressively worsening conduction block. This is why the CAST trial showed that flecainide and encainide increased mortality in post-MI patients with ventricular ectopy - their structurally abnormal, slow-conducting reentrant circuits became fatally exacerbated. In contrast, lidocaine (1B) dissociates so fast it has little effect at resting rates. (Katzung block3.md, p.369-370; Goodman & Gilman block9.md)
Q3. Amiodarone is described as sharing all four Vaughan Williams classes of action. A 65-year-old woman with atrial fibrillation and an EF of 25% is started on amiodarone. The statement that BEST justifies choosing amiodarone over other antiarrhythmics in heart failure is:
A. Amiodarone does not increase mortality in patients with coronary artery disease or heart failure unlike other antiarrhythmics B. Amiodarone has the shortest half-life of all antiarrhythmics, allowing rapid dose adjustment C. Amiodarone selectively blocks IKs and does not prolong the QT interval D. Amiodarone is the only drug that converts atrial fibrillation to sinus rhythm through vagal stimulation E. Amiodarone lacks sodium channel activity, preventing proarrhythmia
Correct Answer: A
Explanation: Katzung explicitly states: "It [amiodarone] is not associated with an increase in mortality in patients with coronary artery disease or heart failure." This is the critical clinical differentiator. Most other antiarrhythmics (flecainide, encainide, sotalol at high doses) increase mortality in structural heart disease via proarrhythmia. Amiodarone's multichannel blockade (Na+, K+, Ca2+, β-adrenergic) with predominantly class III effect makes it effective and relatively safer in HF. Its half-life is extremely long (40-55 days), not short (option B is wrong). It does prolong QT via IKr blockade but rarely causes torsades (option C wrong). (Katzung block3.md, line 1628)

BLOCK 2: Class-Specific Clinical Scenarios

Q4. A 45-year-old man presents with palpitations. ECG reveals WPW syndrome with a rapid, irregular, wide-complex tachycardia. His BP is 100/70 mmHg. Which drug is CONTRAINDICATED in this situation?
A. Procainamide IV B. Amiodarone IV C. DC cardioversion D. IV Verapamil E. IV Flecainide
Correct Answer: D
Explanation: In WPW with pre-excited atrial fibrillation (wide, irregular, fast complex), the accessory pathway bypasses the AV node. Verapamil (and digoxin, adenosine, beta-blockers) block the AV node - this paradoxically accelerates conduction down the accessory pathway by reducing refractoriness and removing concealed retrograde conduction into the bypass tract. The result can be ventricular fibrillation. Procainamide (Class 1A) is actually the drug of choice - it slows conduction in the bypass tract itself. DC cardioversion is appropriate if hemodynamically unstable. (Goodman & Gilman block9.md; Katzung block3.md)
Q5. A 72-year-old man with chronic atrial fibrillation and a history of NYHA class III heart failure (EF 30%) is on digoxin and furosemide. His resting heart rate is 95 bpm. His physician wants to add a drug for rate control. Which drug is preferred?
A. Flecainide - it slows AV nodal conduction via sodium channel blockade B. Verapamil - its calcium channel blockade effectively reduces ventricular rate C. Digoxin dose increase only - it remains the first-line agent in HF D. Beta-blocker (carvedilol/metoprolol succinate) - rate control with proven HF mortality benefit E. Amiodarone only if rhythm control is also needed, avoided for isolated rate control
Correct Answer: D
Explanation: In HF with reduced EF, carvedilol and metoprolol succinate are first-line because they provide rate control AND reduce HF mortality. Verapamil is contraindicated in HFrEF due to its negative inotropic effect. Flecainide is contraindicated in structural heart disease. Digoxin is useful adjunctively (especially as stated by Katzung - "digoxin may be of value in the presence of heart failure") but lacks mortality benefit for rate control alone. The key principle from Katzung: rate control (60-80 bpm) provides better benefit-to-risk outcomes than rhythm control in most AF patients with HF. (Katzung block3.md, lines 1794-1796)
Q6. A 60-year-old woman develops a wide-complex QRS rhythm on telemetry 3 days post-MI. IV procainamide is administered. Which ECG finding would indicate toxicity and mandate stopping the infusion?
A. PR interval prolongation to 220 ms B. QRS widening by more than 50% from baseline C. Development of a new right bundle branch block pattern D. ST-segment depression in V4-V6 E. Heart rate reduction below 50 bpm
Correct Answer: B
Explanation: Procainamide (Class 1A) blocks sodium channels and slows phase 0 depolarization, widening the QRS. The accepted toxic threshold is >50% QRS widening from baseline, which signals excessive sodium channel blockade and imminent risk of proarrhythmia (ventricular tachycardia/fibrillation). This is a standard monitoring rule in antiarrhythmic infusion protocols. Procainamide also prolongs the QT (IKr blockade) - if QTc exceeds 500 ms, that is another stopping criterion. PR prolongation (option A) is a less sensitive endpoint. (Goodman & Gilman block9.md; Katzung block3.md)

BLOCK 3: Proarrhythmia and Toxicity

Q7. A 55-year-old woman with atrial flutter is started on quinidine for rhythm control. On day 3, she presents with syncope. ECG shows a polymorphic ventricular tachycardia with a characteristic pattern. Her QTc is 580 ms. What is the mechanism of this complication?
A. Quinidine causes Class 1C-mediated use-dependent sodium channel block accelerating conduction in the flutter circuit B. Quinidine blocks IKr (KCNH2/HERG channel), prolonging APD and QT interval, predisposing to early afterdepolarizations (EADs) triggering torsades de pointes C. Quinidine causes reflex vagal withdrawal, accelerating the ventricular rate D. Quinidine blocks IKs exclusively, shortening the QT interval and increasing refractoriness heterogeneity E. Quinidine-induced hypocalcemia destabilizes cardiac membranes
Correct Answer: B
Explanation: This describes torsades de pointes (TdP) - the characteristic "twisting of the points" polymorphic VT seen with quinidine. Quinidine (Class 1A) blocks IKr - the rapid component of the delayed rectifier K+ current, encoded by KCNH2 (HERG gene). IKr blockade prolongs APD and QT interval. At slow heart rates (bradycardia-dependent), this prolongation becomes heterogeneous - creating the substrate for early afterdepolarizations (EADs) that trigger TdP. Goodman & Gilman emphasizes that IKr/HERG channel block susceptibility is due to unique pore-lining aromatic residues in KV7.1, making it highly susceptible to many drugs. "Quinidine syncope" is the classic teaching case of TdP. (Goodman & Gilman block9.md, line 2816)
Q8. A 52-year-old man has been on amiodarone 200 mg/day for 3 years for paroxysmal atrial fibrillation. He now presents with dyspnea on exertion, bilateral crackles, and a new restrictive pattern on PFTs with reduced DLCO. What is the mechanism of this toxicity?
A. Amiodarone's iodine content causes hyperthyroidism-induced pulmonary hypertension B. Amiodarone accumulates in lysosomes of alveolar macrophages (it is amphiphilic and cationic), causing phospholipidosis and direct cytotoxic alveolitis C. Amiodarone's Class IV action blocks L-type Ca2+ channels in pulmonary vasculature, causing vasospasm D. Amiodarone-induced hypothyroidism causes pleural effusions mimicking restrictive disease E. Amiodarone upregulates CYP3A4, metabolizing surfactant proteins
Correct Answer: B
Explanation: Amiodarone pulmonary toxicity is one of the most tested adverse effects. Amiodarone is highly lipophilic with an iodine-containing benzofuran ring and a very long half-life of 40-55 days due to extensive tissue accumulation. It is amphiphilic and accumulates in lysosomes of multiple cell types (alveolar macrophages, hepatocytes, thyroid follicular cells, corneal epithelium). This causes phospholipidosis - a lysosomal storage disorder with foamy macrophages - and direct cytotoxic alveolitis progressing to fibrosis. Clinical clues: insidious dyspnea, bilateral infiltrates, reduced DLCO, foamy macrophages on BAL. Occurs in up to 5-10% of patients on long-term therapy. (Katzung block3.md, lines 1617-1622)
Q9. A patient on long-term amiodarone is started on warfarin for a new DVT. INR monitoring is performed. Two weeks after starting warfarin at a standard dose, her INR is 6.8 (target 2-3). What is the pharmacokinetic explanation?
A. Amiodarone induces CYP2C9, increasing warfarin's active (S) enantiomer metabolism B. Amiodarone inhibits multiple CYP450 enzymes (CYP2C9, CYP3A4) increasing warfarin levels - warfarin dose should be reduced by one-third to one-half C. Amiodarone displaces warfarin from plasma protein binding sites, increasing free warfarin D. Amiodarone reduces vitamin K absorption in the gut, potentiating warfarin anticoagulation E. Amiodarone competes with warfarin for renal tubular secretion
Correct Answer: B
Explanation: Katzung explicitly states: "Amiodarone inhibits several cytochrome P450 enzymes and may result in high levels of many drugs, including statins, digoxin, and warfarin. The dose of warfarin should be reduced by one third to one half following initiation of amiodarone, and prothrombin times should be closely monitored." Amiodarone primarily inhibits CYP2C9 (which metabolizes the more potent S-warfarin) and CYP3A4. Since amiodarone has a half-life of 40-55 days, the interaction builds gradually and persists long after amiodarone is stopped. This is a critical drug interaction tested in pharmacology and clinical medicine. (Katzung block3.md, lines 1622-1623)

BLOCK 4: Specific Drug Scenarios (Adenosine, Digoxin, Sotalol)

Q10. A 28-year-old woman presents to the ER with sudden onset palpitations, BP 120/80 mmHg. ECG shows a narrow-complex regular tachycardia at 200 bpm with no visible P waves. After Valsalva maneuver fails, 6 mg IV adenosine is given. The tachycardia terminates abruptly and normal sinus rhythm resumes. What is the mechanism of adenosine's action?
A. Adenosine blocks sodium channels in the AV node, terminating reentry B. Adenosine activates A1 receptors → Gi protein coupling → increases IK(ACh) (K+ efflux, hyperpolarization) and inhibits adenylyl cyclase → depresses AV nodal automaticity and conduction C. Adenosine blocks L-type Ca2+ channels directly via channel pore occupation D. Adenosine releases acetylcholine from vagal terminals, indirectly increasing AV nodal refractoriness E. Adenosine stimulates adenylyl cyclase, increasing cAMP to hyperpolarize AV nodal cells
Correct Answer: B
Explanation: Adenosine acts through A1 purinergic receptors coupled to Gi proteins. This has two effects: (1) it activates IK(ACh) - the acetylcholine-activated K+ channel (same channel that vagal stimulation opens), hyperpolarizing the cell; (2) it inhibits adenylyl cyclase, reducing cAMP and suppressing the funny current (If) and L-type Ca2+ current. The net effect is profound slowing or block of AV nodal conduction - terminating AV-nodal-dependent reentrant tachycardias (AVNRT, AVRT). Adenosine does NOT block sodium channels (it has zero effect on fast-response tissue). The tachycardia described is PSVT (AVNRT). (Goodman & Gilman block9.md; Katzung block3.md - Table 14-2 shows adenosine has 0 Na+ channel blockade and sympatholytic action)
Q11. A 33-year-old man with a known accessory pathway (WPW) receives adenosine for what appears to be PSVT. The narrow-complex tachycardia terminates, but 20 seconds later, an irregular, wide-complex tachycardia develops at 250 bpm. What is the most likely explanation?
A. Adenosine triggered catecholamine release that accelerated the ventricular rate B. Termination of AVRT by adenosine allowed unmasking of pre-existing atrial fibrillation; adenosine also shortened the accessory pathway's refractory period, enabling rapid ventricular conduction C. Adenosine directly converts AF to a more organized flutter with 1:1 conduction D. Adenosine's negative inotropic effect caused cardiogenic shock, altering conduction E. The adenosine bolus caused acute hypokalemia, triggering new VT
Correct Answer: B
Explanation: This represents a well-recognized danger of adenosine in WPW. When adenosine terminates AVRT, it can unmask latent atrial fibrillation. Additionally, adenosine transiently shortens the refractory period of the accessory pathway (by increasing K+ conductance and altering the action potential in accessory pathway tissue differently than in the AV node). The combination of AF + short accessory pathway refractory period = extremely rapid ventricular conduction (pre-excited AF) that can degenerate to VF. This is why adenosine should be used with caution in known WPW, and a defibrillator must be immediately available. (Goodman & Gilman block9.md)
Q12. A 70-year-old man with AF and preserved EF is rate-controlled with digoxin. During a stressful argument, his heart rate spikes to 130 bpm. This occurs because:
A. Digoxin's direct SA and AV nodal calcium channel blockade is overcome by catecholamines at high sympathetic drive B. Digoxin controls rate primarily through vagal enhancement (indirect mechanism); during sympathetic activation, vagal tone is withdrawn, negating digoxin's effect C. Digoxin's Na+/K+-ATPase inhibition becomes reversed under catecholamine stimulation D. Digoxin causes β-receptor upregulation during chronic use, increasing adrenergic sensitivity E. Exercise causes digoxin redistribution from the myocardium into plasma, reducing effective concentration
Correct Answer: B
Explanation: Digoxin's AV nodal slowing relies predominantly on increased vagal tone (indirect mechanism via sensitization of baroreceptors and cardiac vagal afferents) rather than direct nodal depression. During exercise or emotional stress, sympathetic activation dominates over vagal tone - the very mechanism by which digoxin works is neurally opposed. This is why digoxin as monotherapy provides poor rate control during exercise, and why combination with beta-blockers or calcium channel blockers is often needed. Katzung states: "Recent evidence indicates that many patients with atrial fibrillation do as well with simple control of ventricular rate as with conversion to normal sinus rhythm." (Katzung block12.md, line 782; Goodman & Gilman block9.md)

BLOCK 5: Special Scenarios (Dronedarone, Ibutilide, CAST Trial Concepts)

Q13. A 64-year-old man with persistent atrial fibrillation and moderately reduced EF (38%) is being considered for rhythm control therapy. His cardiologist wants to use dronedarone instead of amiodarone to avoid thyroid and pulmonary toxicity. Which consideration would make dronedarone UNSAFE in this patient?
A. Dronedarone requires twice-daily dosing, increasing non-compliance risk B. Dronedarone was shown to increase mortality, stroke, and heart failure in patients with permanent AF or advanced heart failure (ANDROMEDA/PALLAS trials), and is contraindicated in HFrEF C. Dronedarone causes QT prolongation more severe than amiodarone due to retained iodine atoms D. Dronedarone cannot be used with warfarin due to CYP3A4 inhibition causing supratherapeutic INR E. Dronedarone's half-life of 6 hours requires four-times daily dosing in systolic dysfunction
Correct Answer: B
Explanation: Katzung describes: "A study of dronedarone's effects in permanent atrial fibrillation was terminated in 2011 because of increased risk of death, stroke, and heart failure." The PALLAS trial (permanent AF) and ANDROMEDA trial (advanced HF) showed dronedarone caused harm. Dronedarone is contraindicated in permanent AF (as its use requires a commitment to restore sinus rhythm) and in patients with NYHA class III-IV HF or recent decompensation. Dronedarone's iodine atoms were removed (unlike amiodarone) to avoid thyroid toxicity - option C is wrong. Its half-life is ~24 hours (not 6 hours) - option E is wrong. (Katzung block3.md, lines 1633-1642)
Q14. A patient is in the ICU with sustained atrial flutter after cardiac surgery. IV ibutilide is ordered for pharmacological cardioversion. Which adverse effect requires continuous cardiac monitoring for 4 hours after administration?
A. Sinus bradycardia due to excessive vagal activation B. Polymorphic VT (torsades de pointes) due to QT prolongation via IKr blockade C. AV block progressing to complete heart block D. Systemic hypotension due to vasodilation from L-type Ca2+ channel antagonism E. Reflex tachycardia due to baroreceptor inhibition
Correct Answer: B
Explanation: Ibutilide (Class III) acts by activating a slow inward sodium current and blocking IKr, both prolonging the APD and QT interval. The primary and serious adverse effect is torsades de pointes (TdP), occurring in ~4-8% of patients, most commonly in the first 1-4 hours after infusion. Risk factors include female sex, hypomagnesemia, hypokalemia, bradycardia, and prolonged baseline QT. This is why continuous ECG monitoring for at least 4 hours post-infusion is mandatory. IV magnesium should be readily available. Ibutilide's unique mechanism (activates a late Na+ current in addition to K+ channel blockade) distinguishes it from pure IKr blockers. (Katzung block3.md; Goodman & Gilman block9.md)
Q15. The CAST (Cardiac Arrhythmia Suppression Trial) showed that encainide and flecainide, despite suppressing PVCs in post-MI patients, increased mortality 2.5-fold compared to placebo. This finding fundamentally altered the principle of antiarrhythmic therapy. Which concept does this BEST illustrate?
A. PVC suppression is an unreliable surrogate endpoint; reducing ectopy does not equal reducing mortality; Class 1C drugs worsen mortality in structural heart disease due to proarrhythmia in slow-conducting scar B. Beta-blockers should be avoided in post-MI patients because they compete with Class 1C drugs for receptor binding C. Antiarrhythmic drugs should always be combined with ICDs in post-MI patients D. Rate control is superior to rhythm control only in elderly patients above 70 years E. IKr blockade in post-MI tissue shortens the QT interval, increasing VF risk
Correct Answer: A
Explanation: The CAST trial is the pivotal teaching point in antiarrhythmic pharmacology. The trial used PVC suppression as a surrogate endpoint (treating the ECG finding rather than the patient). Class 1C drugs (flecainide, encainide) have slow dissociation kinetics from sodium channels - in post-MI scar tissue with slow, heterogeneous conduction, these drugs further depress phase 0, convert non-reentrant PVCs into sustained lethal reentrant VT/VF. The cardinal lesson: suppressing the surrogate marker does not improve clinical outcomes; it can worsen them. This trial established that ICDs (not drugs) are the primary therapy for high-risk ventricular arrhythmias in structural heart disease. (Katzung block3.md; Goodman & Gilman block9.md)

BLOCK 6: Tough Conceptual/Integration Questions

Q16. A 50-year-old woman presents with recurrent syncope. Her ECG shows a QTc of 510 ms with prominent U waves. Genetic testing reveals a loss-of-function mutation in KCNH2 (HERG gene). Which statement about this condition is MOST accurate?
A. This patient has Short QT Syndrome; dofetilide is the treatment of choice B. This patient has Congenital Long QT Type 2 (LQT2); the mutation impairs IKr, mimicking the effect of Class III antiarrhythmic drugs; treatment includes beta-blockers and avoiding QT-prolonging drugs C. This patient has catecholaminergic polymorphic VT; nadolol is first-line therapy D. Loss-of-function KCNH2 mutations cause gain of inward Na+ current, requiring Class IB drugs E. Mexiletine is the treatment of choice because it shortens the APD via Class IB action
Correct Answer: B
Explanation: KCNH2 (HERG) encodes the alpha subunit of the IKr channel - the rapid component of the delayed rectifier K+ current. A loss-of-function mutation reduces repolarizing K+ current → prolonged APD → prolonged QT → risk of EADs → torsades de pointes. This is the molecular defect underlying LQT2 (the second most common congenital LQTS). The clinical parallel to pharmacology is profound: Class III drugs (dofetilide, sotalol, ibutilide) all block HERG/IKr, mimicking the exact same molecular defect. This is why these drugs cause acquired LQT/TdP. Goodman & Gilman emphasizes: "A common mechanism whereby drugs prolong cardiac action potentials and provoke arrhythmias is inhibition of IKr generated by expression of KCNH2." Treatment: beta-blockers (suppress EAD-triggered activity), avoid QT-prolonging drugs, ICD for high-risk patients. Mexiletine (Class 1B) can actually be used for LQT3 (SCN5A gain-of-function) not LQT2. (Goodman & Gilman block9.md, line 2816)
Q17. A 62-year-old man is on sotalol for paroxysmal AF. He develops diarrhea and stops eating for 2 days before his episode of palpitations and syncope. ECG reveals torsades de pointes. His serum K+ is 2.8 mEq/L. Why does hypokalemia worsen the risk of torsades with sotalol?
A. Hypokalemia activates IKr channels, paradoxically increasing the rate of repolarization and creating electrical heterogeneity B. Hypokalemia causes membrane depolarization that activates IKr channels, increasing QT dispersion C. Low extracellular K+ actually reduces IKr conductance (IKr is paradoxically inhibited at low extracellular K+), further prolonging APD on top of sotalol's IKr blockade; additionally, low K+ promotes EAD formation D. Hypokalemia activates NCX (Na+-Ca2+ exchanger) in reverse mode, causing intracellular Ca2+ overload that triggers DADs E. Sotalol is protein-bound; hypokalemia increases free sotalol levels by competitive albumin displacement
Correct Answer: C
Explanation: This is a high-yield subtlety from cardiac electrophysiology. Paradoxically, IKr channel conductance is reduced at low extracellular K+ concentrations (normally, IKr increases as extracellular K+ rises). This means hypokalemia itself lengthens the APD and QT interval via the same HERG/IKr pathway. When combined with sotalol (an IKr blocker), the effects are synergistic - producing a far greater QT prolongation than either alone. This explains why hypokalemia/hypomagnesemia are major risk factors for drug-induced TdP, and why correcting electrolytes is the first step when TdP occurs. (Goodman & Gilman block9.md)
Q18. A 48-year-old male with idiopathic dilated cardiomyopathy (EF 25%) experiences recurrent ICD shocks for VT. His electrophysiologist wants to add IV amiodarone to reduce shock frequency. He is also on warfarin (INR 2.5), digoxin, and atorvastatin. Which TWO drug interactions require immediate dose adjustment?
A. Atorvastatin and warfarin B. Digoxin and warfarin C. Only warfarin D. Amiodarone with metoprolol and aspirin E. No interactions expected at standard amiodarone doses
Correct Answer: B
Explanation: Amiodarone inhibits CYP2C9 (metabolizes warfarin) → warfarin levels increase → bleeding risk. Amiodarone also inhibits P-glycoprotein (P-gp) renal tubular secretion of digoxin → digoxin levels increase → digoxin toxicity (nausea, vomiting, bradycardia, arrhythmias). Katzung states directly: "Amiodarone inhibits several cytochrome P450 enzymes and may result in high levels of many drugs, including statins, digoxin, and warfarin. The dose of warfarin should be reduced by one third to one half." Atorvastatin levels also rise (CYP3A4 inhibition) increasing myopathy risk - but of the listed options, digoxin and warfarin are the most clinically urgent adjustments. (Katzung block3.md, line 1622-1623)
Q19. During electrophysiology study, a patient undergoes programmed stimulation. At which point in the cardiac action potential are sodium channel-blocking antiarrhythmic drugs MOST effective at reducing sodium current?
A. Phase 4 (spontaneous diastolic depolarization) - channels are in the rested state, highly accessible B. Phase 0 (rapid upstroke) and Phase 2 (plateau) - channels are in activated and inactivated states respectively; drug binding is highest because the receptor is accessible in both active and inactivated configurations C. Phase 3 (rapid repolarization) - channels are transitioning, creating a high-affinity binding window D. The period immediately after repolarization when channels have fully recovered to rested state E. Drugs bind equally across all phases of the action potential
Correct Answer: B
Explanation: Katzung describes the "state-dependent" model precisely: "Therapeutically useful channel-blocking drugs bind readily to activated channels (during phase 0) or inactivated channels (during phase 2) but bind poorly or not at all to rested channels." During Phase 0, channels are rapidly activated (open state) - highly accessible. During Phase 2 (plateau), channels are in the inactivated (closed but non-conducting) state - still highly accessible for drug binding. During Phase 4 and after complete repolarization, channels are in the rested state - drug binding is minimal. This is the molecular basis of use-dependency: at fast heart rates (more activations + inactivations per unit time), less recovery to rested state, so more drug-channel binding occurs. (Katzung block3.md, lines 1332-1338)
Q20. A 55-year-old man with persistent AF fails rate control with beta-blockers and diltiazem (rate 90-100 bpm at rest). He is in NYHA class II HF (EF 40%). For rhythm control, which of the following drugs is the MOST APPROPRIATE first choice?
A. Flecainide 200 mg twice daily - most potent Class 1C rhythm control agent B. Sotalol 80 mg twice daily - Class III with additional beta-blocker effect C. Dofetilide (Class III) or amiodarone - guided by the AF drug-selection algorithm based on presence/type of structural heart disease D. Quinidine - first-line for AF with mild HF per ACC/AHA guidelines E. Propafenone - safe in HF with EF 40% when combined with AV nodal agent
Correct Answer: C
Explanation: This question tests the AF drug-selection algorithm (Katzung Figure 14-11). Key principle: drug selection for rhythm control in AF depends on the presence and type of underlying heart disease:
  • No structural heart disease: Flecainide, propafenone, dronedarone (or sotalol) are acceptable
  • CAD: Sotalol, dofetilide, or amiodarone
  • HFrEF (EF <35-40%): Only amiodarone or dofetilide are safe; Class 1C drugs (flecainide, propafenone) are contraindicated due to proarrhythmic risk in structural disease
  • LVH: Amiodarone preferred
This patient has HF with mildly reduced EF - Class 1C drugs risk life-threatening proarrhythmia. Sotalol can worsen HF due to beta-blockade. Amiodarone or dofetilide are the appropriate choices. (Katzung block3.md, lines 1798-1810; Goodman & Gilman block9.md)

QUICK SUMMARY TABLE

MCQDrug/ConceptCore Principle
Q1LidocaineState-dependent Na+ channel block; chronic depolarization in ischemia
Q2FlecainideSlow dissociation → CAST trial, proarrhythmia post-MI
Q3AmiodaroneMultichannel; safe in HF; no mortality increase
Q4VerapamilContraindicated in WPW+AF; AV block → rapid bypass conduction
Q5Beta-blockersRate control in HFrEF; verapamil contraindicated
Q6Procainamide>50% QRS widening = toxicity endpoint
Q7QuinidineIKr blockade → TdP; "quinidine syncope"
Q8AmiodaronePulmonary toxicity; phospholipidosis via lysosomal accumulation
Q9AmiodaroneCYP2C9/3A4 inhibition; warfarin dose -1/3 to -1/2
Q10AdenosineA1 Gi → IK(ACh) + inhibits adenylyl cyclase; terminates AVNRT
Q11Adenosine in WPWUnmasks AF + shortens AP accessory pathway → dangerous
Q12DigoxinVagal mechanism; ineffective during sympathetic activation
Q13DronedaroneContraindicated in permanent AF and advanced HF (PALLAS trial)
Q14IbutilideTdP risk; 4-hour monitoring post-infusion
Q15CAST trialSurrogate endpoint fallacy; Class 1C increase mortality post-MI
Q16LQT2 / HERGKCNH2 loss-of-function = IKr decrease = congenital LQTS
Q17Sotalol + hypoKIKr paradoxically reduced at low extracellular K+ → synergistic QT prolongation
Q18Amiodarone interactionsDigoxin (P-gp) + warfarin (CYP2C9) dose adjustment mandatory
Q19Na+ channel blockActivated (Phase 0) + Inactivated (Phase 2) states → state-dependent block
Q20AF rhythm controlEF 40% HF → only amiodarone or dofetilide; 1C contraindicated
Sources:
  • Katzung's Basic and Clinical Pharmacology, 16th Edition - Chapter 14: Antiarrhythmic Drugs (blocks 3 & 12)
  • Goodman & Gilman's Pharmacological Basis of Therapeutics - Chapter 34: Antiarrhythmic Drugs (block 9)
  • Goldman-Cecil Medicine - Antiarrhythmic Therapy (block 7 & 20)
This is a shared conversation. Sign in to Orris to start your own chat.